TriNetX Secures $40 Million in Series D Funding to Advance AI-Driven Clinical Research Platform

TriNetX, a health research company headquartered in Cambridge, Massachusetts, announced that it has secured $40 million in Series D financing. The round was led by Merck’s Global Health Innovation Fund and included participation from existing investors MPM Capital, F2 Ventures, and Deerfield Management, as well as new investors Mitsui & Co., Itochu Corporation, and Itochu Technology Venture Capital. This brings TriNetX’s total funding to $102 million. The investment will be used to drive the company’s expansion into Europe, Asia, and South America, and to further advance its artificial intelligence and digital clinical trial technologies.

Gadi Lachman, CEO of the company, stated that at the time of securing investment, TriNetX’s revenue had grown by 200% year-over-year, far exceeding eight figures. The company currently supports electronic health record and genomics analysis, covering more than 300 million patients across hundreds of healthcare institutions in 17 countries, including the United States, the United Kingdom, Germany, Italy, Japan, Singapore, India, and Brazil. Its clients include pharmaceutical giants such as Novartis, Sanofi, and Pfizer.

Gadi Lachman stated, “The landscape of clinical research is evolving, with the industry increasingly driven by data to support clinical studies and regulatory oversight. TriNetX is at the forefront of this industry transformation. We have created an exclusive real-world evidence ecosystem that integrates data, analytics, and a community of researchers, thereby facilitating the design of randomized or pragmatic clinical trials and supporting various observational studies, including retrospective or prospective, controlled or longitudinal studies.”

David Fusari, former Chief Architect of Microsoft’s Healthcare Solutions Group, is the creative force behind TriNetX. The company offers three cloud-based subscription services—TriNetX Research, TriNetX Download, and TriNetX Analyze—that comply with the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the European Union’s General Data Protection Regulation (GDPR), with the aim of simplifying the medical research process. Together, these services constitute a suite of tools for trial design, cohort analysis, and site selection, enabling users to query and download data from a database comprising “billions” of clinical facts, including discharge summaries, laboratory results, vital signs, and in-depth specialized information across therapeutic areas.

Furthermore, TriNetX leverages natural language processing technology from Averbis, a German company, to extract unstructured data from patients’ physician records. This data is subsequently mapped to standardized clinical terminologies to supplement incomplete medical records. Clients can upload documents and associated metadata to designated directories on TriNetX hardware appliances. Combined with recently launched algorithms, this capability enables the elucidation of specific chemotherapy administration processes and patient circumstances, including data from tumor registries and pathology reports.

The company’s ultimate goal is to lower the barriers to clinical research. TriNetX enables researchers to perform tasks such as tracking patient treatments to identify when and why therapy changes occur, or applying customized statistical models to generate predictions, without requiring direct access to clinical data.

Joe Volpe, Vice President and Managing Director of the Merck Global Health Innovation Fund, stated, “Real-world data is critically important for clinical trials, drug research, and medical discoveries. TriNetX has facilitated industry-wide information exchange on a global scale, and data sharing has the potential to rapidly provide answers to complex questions. With TriNetX, tasks that previously took days or weeks to complete can now be accomplished in just minutes. This is why we actively participated in this round of financing; we hope to see the further development and broader adoption of TriNetX’s products.”

(Editor: Wang Shan)